<p>This application provides a method of preferentially inhibiting monoamine oxidase A (MAOA) in the brain of a subject relative to in the intestine of the subject comprising parenterally administering to the subject a controlled release formulation comprising a therapeutically effective amount of rasagiline or a pharmaceutically acceptable salt thereof.</p>
申请公布号
CA2882072(A1)
申请公布日期
2014.02.20
申请号
CA20132882072
申请日期
2013.08.16
申请人
TEVA PHARMACEUTICAL INDUSTRIES LTD.
发明人
FITZER-ATTAS, CHERYL;ELIAZ, ROM E.;BLAUGRUND, ERAN;GROSS, AVIVA;MAYK, ADI